Publicacións en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (17)

2024

  1. Criteria and indicators to evaluate quality of care in genitourinary tumour boards

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1639-1646

  2. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

    Clinical and Translational Oncology, Vol. 26, Núm. 6, pp. 1532-1538

  3. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study

    Clinical and Translational Oncology

  4. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

  5. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

    Clinical and Translational Oncology

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

2020

  1. Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

    Therapeutic Advances in Medical Oncology, Vol. 12

  2. Latest progress in molecular biology and treatment in genitourinary tumours

    Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195

2018

  1. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

2017

  1. Docetaxel in prostate cancer: A familiar face as the new standard in a hormone-sensitive setting

    Therapeutic Advances in Medical Oncology, Vol. 9, Núm. 5, pp. 307-318

  2. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

    The Lancet Respiratory Medicine, Vol. 5, Núm. 5, pp. 435-444

  3. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

    Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421

  4. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment

    Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190

  5. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges

    Expert Review of Anticancer Therapy, Vol. 17, Núm. 3, pp. 217-226

2016

  1. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations

    Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141

2015

  1. New advances in genitourinary cancer: evidence gathered in 2014

    Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 443-464

2014

  1. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 6, pp. 1095-1107